Stanley Laman Group Ltd. increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 125,732 shares of the medical equipment provider’s stock after purchasing an additional 5,639 shares during the quarter. Hologic makes up approximately 1.2% of Stanley Laman Group Ltd.’s portfolio, making the stock its 21st biggest holding. Stanley Laman Group Ltd.’s holdings in Hologic were worth $5,375,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of HOLX. Ontario Teachers Pension Plan Board increased its holdings in shares of Hologic by 12.6% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 69,990 shares of the medical equipment provider’s stock worth $2,992,000 after purchasing an additional 7,811 shares during the period. American International Group Inc. increased its holdings in shares of Hologic by 8.0% in the fourth quarter. American International Group Inc. now owns 107,449 shares of the medical equipment provider’s stock worth $4,593,000 after purchasing an additional 7,982 shares during the period. TCW Group Inc. bought a new position in shares of Hologic in the fourth quarter worth $547,000. Homrich & Berg bought a new position in shares of Hologic in the fourth quarter worth $219,000. Finally, Advisory Services Network LLC increased its holdings in shares of Hologic by 1,075.7% in the fourth quarter. Advisory Services Network LLC now owns 26,253 shares of the medical equipment provider’s stock worth $1,122,000 after purchasing an additional 24,020 shares during the period. 95.24% of the stock is currently owned by institutional investors and hedge funds.
Hologic, Inc. (HOLX) opened at $39.29 on Monday. Hologic, Inc. has a 1 year low of $35.33 and a 1 year high of $46.80. The stock has a market cap of $10,864.83, a price-to-earnings ratio of 10.37, a P/E/G ratio of 1.77 and a beta of 0.77. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98.
Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. During the same period in the previous year, the business earned $0.52 earnings per share. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. analysts predict that Hologic, Inc. will post 2.25 EPS for the current fiscal year.
In other Hologic news, Director Namal Nawana purchased 6,600 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the completion of the transaction, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.88% of the company’s stock.
HOLX has been the topic of several research analyst reports. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a report on Wednesday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target (up previously from $48.00) on shares of Hologic in a report on Tuesday, January 9th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target on the stock in a report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Thursday, November 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $48.00.
ILLEGAL ACTIVITY WARNING: “Stanley Laman Group Ltd. Boosts Position in Hologic, Inc. (HOLX)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/19/stanley-laman-group-ltd-boosts-position-in-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.